

Citibank N.A.
Securities Services
FIFC, 11th Floor,
C-54 & C-55, G-Block,
Bandra Kurla Complex,
Bandra (East)
Mumbai – 400 098, India

T +91 22 6175 7999 / 4502 7999
F +91 22 2653 2348



Dated: 21st June 2024

**To,
The Legal & Compliance Division,
National Stock Exchange,
Exchange Plaza, B.K.C.
Bandra (E)
Mumbai - 4000051**

Reporting under Substantial Acquisition of Shares and Take over Regulations, 2011 of Securities & Exchange Board of India ("SEBI")

Dear Sir,

We on behalf of and as authorized representatives of our below mentioned client wish to make the necessary disclosures as required under the **Substantial Acquisition of Shares and Take over Regulations, 2011 of Securities & Exchange Board of India ("SEBI")**

Please find below the relevant details in this regard for your ready reference. In this connection, we have also enclosed herewith the necessary disclosure forms.

Name of the acquirer & PAC with the acquirer	ORBIMED ASIA III MAURITIUS FVCI LIMITED
SEBI Registration No.	ORBIMED ASIA III MAU
Scrip	ADVANCED ENZYME TECHNOLOGIES LIMITED
Total Holdings (No. of Shares)	13,509,522
Paid Up Equity Capital (No. of Shares)	111,824,075
% Fluctuation	9.88 % (Last Reported at 2.20%)
Current % Holding	12.08%

In view of the aforesaid, you are requested to take this on records and do the needful. For any further queries in this regard, please contact us on 91-22-6175 6960.

Thanking You,

Truly Yours,
By Constituted Attorney


Sagar Madan
Enclosures: As above.